Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
ORGANIZATION
Fast-Track Approval System, New Pricing Rules Needed for Therapeutic Apps: DTx Consortium
The Japan Digital Therapeutics Consortium, which is made up of seven companies including drug makers developing therapeutic apps, is calling for the introduction of a fast-track approval system and new pricing rules for such products. Rie Fukaya, global clinical regulatory…
To read the full story
Related Article
- Japan’s 1st Therapeutic App Now Available: CureApp
December 2, 2020
- Keidanren Calls for Clearer Classification Criteria for “Software as a Medical Device” to Promote Development
October 21, 2020
- Mitsubishi Tanabe to Develop Mobile App for Depression Treatment
September 3, 2020
- Astellas Links Up with US Health Tech Welldoc in Digital Therapeutics
November 22, 2019
- Shionogi Bags Japan/Taiwan Rights to Akili’s Digital Medicines for ADHD, Autism
March 8, 2019
ORGANIZATION
- Medipal’s Choufuku Takes Over as JPWA Vice Chair
November 4, 2026
- Enhertu, Dupixent Win 2026 International Prix Galien Biotechnology Award
November 2, 2026
- Pharma Trade Groups Flag Potential Leak of 30,000 Email Addresses
November 2, 2026
- Pharma Urges Drug Security, Demands 8.5% Price Hike: LDP Hearing
October 30, 2026
- Pharma Labor Group Seeks Political Push for Price Hikes, Fair Cost Sharing
October 30, 2026
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…